U.S. Pates Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collecte

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Barto		10713333			
		2003-11-13			
		on et al.			
Art Unit		2876			
Examiner Name Unkn		iown			
Attorney Docket Numb	er	112703-295			

		Remove				
Examiner   Cite   Patent Number   Kind   Code1		Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	4645036		1987-02-24	Nestier	
	2	6193154		2001-02-27	Philips et al.	
	3	5992570 1999-11		1999-11-30	Walter et al.	
	4	6021362		2000-02-01	Maggard et al.	
	5	6116505		2000-09-12	Withrow	
	6	6356794		2002-03-12	Perin et al.	
	7	6598790		2003-07-29	Horst	
lf you wish	to ac	ld additional U.S. Pa			lease click the Add button.	Add Remove

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10713333		
Filing Date		2003-11-13		
First Named Inventor Barto		n et al.		
Art Unit		2876		
Examiner Name Unkn		own		
Attornou Docket Number		112703-205		

Examiner Initial*	Cite No	Publicat	ion Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Patentee or Applicant Relevant			Columns,Lines where nt Passages or Releva Appear			
	1	2002014	5037		2002-10-10		Goodwin						
	2	2005012	8087		2005-06-16		Claessens et al.						
If you wisl	h to a	dd additio	nal U.S. Publi	shed Ap	plication	n citatio	n information p	ole as	se click the Ad	d butto	n. Add		
					FOREIG	GN PAT	TENT DOCUM	ENT	s		Remove	•	
Examiner Initial*	Cite No	Foreign Number	Document 3	Country Code <sup>2</sup>		Kind Publication Name of Patentee or where Rele			or Relevant	т			
	1												
If you wis	h to a	dd additio	nal Foreign Pa	atent Do	cument	citation	information pl	ease	e click the Add	button	Add		
				NON	I-PATE	NT LITE	RATURE DO	CUN	MENTS		Remove	0	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Τŝ					
	1 International Search Report for Infernational Patient Application No. PCT/US05/28545 that corresponds to the present application and of which the references cited above was cited therein.												
If you wis	h to a	dd additio	nal non-paten	t literatu	re docu	ment cit	ation informati	on p	olease click the	Add b	utton A	dd	
					EX	AMINE	R SIGNATUR	E					
Examiner	Signa	ature							Date Conside	ered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE	Application Number		10713333
	Filing Date		2003-11-13
	First Named Inventor Barto		n et al.
(Not for submission under 37 CFR 1.99)	Art Unit		2876
(Notice submission director of the 1994)	Examiner Name Unkn		own
	Attorney Docket Numb	er	112703-295

See four Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. \* Exister office in all assets for electrons, by the loss letter code (WPO) Standard 51.3. \* \*Projectioned projection pr

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10713333
Filing Date		2003-11-13
First Named Inventor Barton		n et al.
Art Unit		2876
Examiner Name	Unkn	IOWTI
Attorney Docket Number		112703-295

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
7	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(e)(1)

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tent of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(d).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

### □ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Matthew T. Ridsdale/	Date (YYYY-MM-DD)	2006-04-20
Name/Print	Matthew T. Didedala	Registration Number	56832

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 3T CFR. 11.4 This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.